Short News

Print

 

short news


KEMCOLIANS Forum welcomes appointment
of permanent VC at KEMU

LAHORE: King Edward Medical College graduates (KEMCOLIANS) Forum has welcomed the appointment of Prof. Faisal Masood as permanent Vice Chancellor of King Edward Medical University. They believe that the vision of the new VC to concentrate on core function of teaching and training of medical students is laudable and it will go a long way in improving the medical education in the institution.


 Substituting Prasugrel for Clopidogrel in 
triple therapy may increase bleeding risk

“Substituting prasugrel (Effient) for clopidogrel (Plavix) in stented patients on triple therapy may increase the risk of bleeding,” according to a study (3/22) published in the Journal of the American College of Cardiology. Investigators found, “in a single-center study,” that “there was no difference in cardiovascular events between the antiplatelet agents, but significantly more patients hit a primary endpoint of TIMI major and minor bleeding with the newer drug (28.6% versus 6.7%, P<0.001).”
CardioSource (3/22) reports that the study “was based on 377 patients who underwent DES implantation and had an indication for oral anticoagulation (OAC) between Feb. 2009 and Dec. 2011.” Participants “were treated with aspirin and OAC with either prasugrel or clopidogrel for six months.” Courtesy: CardioSource.org


 New oral anticoagulants not superior to Warfarin

for secondary prevention of stroke

“Collectively, three members of the new generation of oral anticoagulants are no more effective than warfarin for the secondary prevention of stroke in patients with nonvalvular atrial fibrillation, concluded an analysis that aggregated data from three large randomized trials.” Researchers found that “the new agents did appear, however, to significantly reduce the risk of hemorrhagic stroke compared with the older drug.” Additionally, when “looking specifically at patients with a history of stroke or transient ischemic attack (TIA), the analysis...saw no relative difference in secondary stroke-prevention efficacy among the three agents, which were dabigatran etexilate (Pradaxa, Boehringer Ingelheim), apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), and rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals).” The findings were presented at the recent American College of Cardiology meeting.

© Professional Medical Publications. All rights reserved.